Enterprise Value
-127.4M
Cash
193.5M
Avg Qtr Burn
-35.16M
Short % of Float
6.30%
Insider Ownership
21.70%
Institutional Own.
59.76%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Aldafermin (MK-3655) Details Non-alcoholic steatohepatitis , Fibrosis | Phase 2b Update | |
Aldafermin (FGF19) Details Irritable bowel syndrome, Bile acid malabsorption | Phase 2 Update | |
NGM621 ( humanized IgG1 monoclonal antibody) Details GA (Geographic Atrophy) | Phase 2 Update | |
NGM707 Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
NGM120 Details Pancreatic cancer, Cancer, Solid tumor/s | Phase 1/2 Data readout | |
NGM831 Details Solid tumor/s, Cancer | Phase 1b Data readout | |
NGM438+ KEYTRUDA® Details Solid tumor/s, Cancer | Phase 1b Data readout | |
Aldafermin (FGF19) Details Non-alcoholic steatohepatitis , Liver disease | Failed Discontinued |